Insmed gains US approval of lung disease drug forecast to be blockbuster
Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not caused by cystic fibrosis.
Previous Post
Targeting Amyloid-ß Oligomers With Investigational Alzheimer Disease Therapy Valiltramiprosate
Next Post
MCAT Score: How is the MCAT Scored?
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago